The Reveal LINQ™ Insertable Cardiac Monitor (ICM) is an implantable monitoring system that records subcutaneous electrocardiograms (ECGs) and is indicated for human clinical use for: 1) patients with clinical syndromes or situations at increased risk of cardiac arrhythmias and 2) patients who experience transient symptoms that may suggest a cardiac arrhythmia [ 19].
This latency could either be biologically determined, reflecting an origin of these late-appearing clones from their normal counterparts with similar features, or simply reflective of a stochastic process, as previously indicated for established human breast cancer cell lines passaged in vivo. 5.
This latency could either be biologically determined, reflecting an origin of these late-appearing clones from their normal counterparts with similar features, or simply reflective of a stochastic process, as previously indicated for established human breast cancer cell lines passaged in vivo.
aThe UniProt ID, MW and FFAT motif are indicated for the human proteins.
According to data sheets for medicines indicated for usage in humans and animals, meloxicam hinders the accumulation of leukocytes in inflamed skin and other tissues [ 11].
Clindamycin is indicated for the treatment of human staphylococcal and streptococcal pneumonia (among other aerobic and anaerobic infections).
Biocompatible with fibroblasts and keratinocytes, tissue engineered skin is indicated for regeneration and remodeling of human epidermis and wound healing improving the treatment of severe skin defects or partial-thickness burn injuries.
Chemotherapy is considered indicated for most patients with 'Luminal B', 'Human Epidermal growth factor Receptor 2 (HER2) positive', and 'Triple negative (ductal)' disease, with the addition of trastuzumab in 'HER2 positive' disease.
This indicates, also for humans, that the capacity for accumulation of PFBS in serum is lower than for long-chain homologues.
The mir-134 cluster is excluded from this list (its known members are indicated separately for human, mouse and rat in the MR 6.0 column).
This indicates that, for human patients administered LRRK2 inhibitors, the phosphorylation status of LRRK2 at Ser and Ser in blood cells could be employed as a biomarker of LRRK2 inhibitor activity.
